Modality
Multispecific
MOA
CD3xCD20
Target
AHR
Pathway
PD-1/PD-L1
CMLPancreatic Ca
Development Pipeline
Preclinical
Apr 2024
→ Oct 2029
PreclinicalCurrent
NCT07488929
2,437 pts·CML
2024-04→2029-10·Terminated
2,437 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-103.5y awayInterim· CML
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2029-10-10 · 3.5y away
CML
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07488929 | Preclinical | CML | Terminated | 2437 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR |